Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency
Status:
Active, not recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
CAEB1102-300A is a multi-center randomized, double-blind, placebo-controlled study to
evaluate the safety and efficacy of pegzilarginase in patients with ARG1-D. This study will
consist of a screening period; a randomized, double-blind treatment period; a long-term
extension; and a follow up visit for final safety assessments.